Michael Bookman
0000-0002-4255-7814
3 papers found
Refreshing results…
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
Missing publications? Search for publications with a matching author name.